A Study of CAR-T Cells Targeting Autoimmune Diseases
ConditionAutoimmune Diseases
Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-65
SponsorBeijing Boren Hospital
About this trial
The purpose of this study is to assess the safety and efficacy of CAR-T cell therapy in patients with autoimmune disease.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Male or female, between 18 and 56 years old;
Diagnosed with Autoimmune Diseases；
Good organ functions;
Voluntary participates this trial and can comprehend and sign ICF.
Disqualifiers
Had or has active malignancy;
Had been subjected to treatment by CD19 targeted therapy or CAR-T therapy or any gene therapy;
Combined with other autoimmune disease that needs treatment;
Pregnant or lactating women;
Trial design
Design model
Single group
Treatments tested in this trial
CAR-T
DrugCAR-T cells
Treatment groups
12 Participants
are divided into 1 treatment groupGroup A: CAR-T treatmentExperimental treatment 1 intervention
Trial outcomes
Primary outcomes
1
Dose Limiting Toxicity
Time frame
0~28 day after treatment2
Frequency of AEs, SAEs
Time frame
0 day to 24 months after treatmentSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov
This trial is not recruiting at the moment. You can still explore other options: